Personalized Medicines: Market Research Report

January 2019 | 313 pages | ID: P261BB3F9EDEN
Global Industry Analysts, Inc

Abstracts

This report analyzes the worldwide markets for Personalized Medicines in US$ Million by the following Segments: Targeted Therapeutics, and Tests & Lab Services.

The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia-Pacific, and Rest of World. Annual estimates and forecasts are provided for the period 2016 through 2024.

Also, a five-year historic analysis is provided for these markets. Market data and analytics are derived from primary and secondary research.

Company profiles are primarily based on public domain information including company URLs. The report profiles 87 companies including many key and niche players such as -

• Abbott Molecular, Inc.
• Beckman Coulter Genomics
• bioMérieux SA
• Bristol-Myers Squibb Company
• Dako Denmark A/S
• F. Hoffmann-La Roche Ltd.

Contents

I. INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS

Study Reliability and Reporting Limitations
Disclaimers
Data Interpretation & Reporting Level
Quantitative Techniques & Analytics
Product Definitions and Scope of Study
Personalized Medicine

II. EXECUTIVE SUMMARY

1. INDUSTRY OVERVIEW

Access to Valuable Genetic Information Ushers Transformation in Medicine
Market Outlook
Adoption of Personalized Medicines – A Peek into Developed and Developing Economies
Increasing Market Availability of Personalized Medicines
Select Key Approved Personalized Medicines and Associated Biomarkers by Therapeutic Area

Table 1. Leading Personalized Medicines Worldwide (2015-2017): Annual Sales of Select Leading Medicines in US$ Million (includes corresponding Graph/Chart)

Constraints in Traditional Approach to Treatment Creates Need and Demand for Personalized Medicine

Table 2. Drug Ineffectiveness for Select Therapeutic Categories as a Percentage of Patient Population (includes corresponding Graph/Chart)

Economics of Personalized Medicine
Is Emergence of Personalized Medicine Signaling the End of Blockbusters?

2. MARKET DRIVERS AND RESTRAINTS

Growth Drivers in a Gist
Key Market Restraints
Increasing Incidence and Prevalence of CDDs: A Major Growth Driver
Oncology – A Major Application Market
Diagnosed Cases of Cancer on the Rise
World Cancer Statistics: Incidence and Mortality Data

Table 3. Global Cancer Incidence (2015): Number of New Cancer Cases in Thousands by Type and Gender (includes corresponding Graph/Chart)

Table 4. Global Cancer Mortality (2015): Number of Cancer Related Deaths in Thousands by Type and Gender (includes corresponding Graph/Chart)

Growing Cancer Cases in Developing Countries Bodes Well for the Personalized Medicine Market
Growing Importance of Personalized Drugs for Cancer Treatment
Ballooning Global Population Offers Significant Growth Opportunities

Table 5. World Population (In Million) for the Years 2018, 2022, 2025, 2030, 2035, 2040, 2045 and 2050 (includes corresponding Graph/Chart)

Table 6. Top 25 Countries Worldwide in Terms of Population: 2015 & 2016 (includes corresponding Graph/Chart)

Aging Global Population Drives Personalized Medicines

Table 7. Global Aging Population (in Thousands) by Age Group: 1975-2050 (includes corresponding Graph/Chart)

Table 8. Global Aging Population in Select Regions/Countries: Population of 60+ Individuals in ‘000s and as a Percentage of Total Population for 2015 & 2050 (includes corresponding Graph/Chart)

Table 9. Global Population Statistics for the 60+ Age Group by Region (2017) (includes corresponding Graph/Chart)

Table 10. Global Life Expectancy at Birth (Years) by Geographic Region: 1950-2050 (includes corresponding Graph/Chart)

Table 11. Life Expectancy for Select Countries in Number of Years: 2016 (includes corresponding Graph/Chart)

Increasing Healthcare Spending in Emerging Markets

Table 12. Healthcare Spending as a Percentage of GDP by Region (2016) (includes corresponding Graph/Chart)

Table 13. Per-Capita Healthcare Expenditure in US$ for Select Countries/Regions (2016) (includes corresponding Graph/Chart)

Changing Patients’ Trends Drive Personalized Medicine
Technological Advancements and Consumer Push to Drive Personalized Medicine

3. MARKET TRENDS & ISSUES

Minimizing Adverse Events – A Major Benefit of Personalized Medicines
Personalized Medicines Brings Disease Prevention Closer to Reality
Ability to Manage Healthcare Costs Piques Industry and Government Alike
Potential to Uncover Additional Prospective Targets – A Major Benefit in Pursuit
Elimination of Invasive Tests Attracts Patients and Doctors towards Molecular Test-based Personalized Medicines
Genomics to Dictate Advancement of Personalized Medicines
Companion Diagnostics Drive Personalized Medicine
Biomarkers as Companion Diagnostics
Personalized Medicines Help Reducing R&D Costs
Personalized Medicine – A Corporate Growth Strategy
Development Pipeline Reveals Promising Picture for Personalized Medicine
Advancements in Biomedical Imaging to Enhance Personalized Medicines
Increasing Use of Personalized Medicines Drives Genetic Testing
Genetic Testing: The Rapidly Growing Segment of Molecular Diagnostics Market
Next-Generation Sequencing – A Giant Leap in Genome Sequencing
Single Nucleotide Polymorphism (SNP) – Making Advancements in Personalized Medicine
Personalized Medicine Goes Beyond DNA Analysis
Combination Approaches May Mark Future Endeavors
Need for New Designs in Clinical Trials Emerges in Therapies for Rare Cancers
Immunotherapy for Cancers – A Potential Breakthrough in the Sector
Personalized Medicine Industry – Inundated with Data
Advanced Computing Technologies – The Need of The Hour to Analyze Large Data
Artificial Intelligence Revolutionizing Personalized Medicine
Challenges Aplenty for Precision Medicine
Lack of Clinically Useful Diagnostic Tests – Growth Dampener
Pricing and Value Dilemma Haunts Personalized Medicines
Bedside Biopharmaceutical Production to Dramatically Reduce Cost of Personalized Medicine

4. PRODUCT OVERVIEW

Personalized Medicine
Benefits of Personalized Medicines
Few Applications of Personalized Medicine
Colorectal Cancer
Blood Clots
Breast Cancer
Diagnostics in Personalized Medicine
Genetic Tests
Companion Diagnostics
Genetic Testing
Types of Genetic Testing
Prenatal Diagnosis
Cancer Testing
Carrier Identification
Newborn Screening
Predictive Testing
Pre-Symptomatic Testing
Cytogenetic Tests
Proteomics: A Critical Drug Discovery Tool
Proteomics and Genomics: A Comparison

5. PRODUCT INTRODUCTIONS AND APPROVALS

Somalogic Teams Up with Leeds University for Personalized Medicines
University of Tokyo Sings Alliances for Developing Personalized Cancer Vaccine
Helomics and Ariel Ink Service Agreement to Commercialize PancreasDx Genomic Assay
Skyline Licenses Illumina’s MiSeqDx NGS Platform
Genoptix to Acquire Rosetta
DTU Bioinformatics Inks MoU with ASTAR
Bayer Inks Agreement with Loxo Oncology for Investigational Personalized Cancer Therapies
HealthSystem Joins Hands with Ambry Genetics to Advancing Precision Medicine Development
Invitrocue Establishes Joint Lab with ASTAR to Develop Personalized Medicine
OneOme and ProZed Partner to Bring Personalized Medicine to Canada
Insilico Medicine Launches ALS. AI Platform
Sysmex to Acquire Oxford Gene Technology
CVI to Partner with Panaceutics
Panaceutics Acquires Triangle Compounding Pharmacy
Acobiom Secures Funding from Bpifrance for OncoSNIPE Project
Genospace Merges with Sarah Cannon
QNRF and QGP Launch Second Cycle of Path Towards Personalized Medicine
VieCure and Avera Team Up for Personalized Medicine
PierianDx Acquires Tute Genomics
iConquerMS Launches REAL MS Study
IntelliCyt Collaborates with NoTable Labs to Advance Predictive Personalized Medicine Platform
Thermo Fisher Partners with West China Hospital to Develop Precision Medicine
Swagene Introduces Personalized Medicine for Blood Cancer in Children
Macrogen Inks Joint Research Agreement with National Cancer Center Korea
Contextual Genomics Launches Phase II of Find It Genomics Test

6. FOCUS ON SELECT PLAYERS

Abbott Molecular, Inc. (USA)
Beckman Coulter Genomics (USA)
bioMérieux SA (France)
Bristol-Myers Squibb Company (USA)
Dako Denmark A/S (Denmark)
F. Hoffmann-La Roche Ltd. (Switzerland)
GlaxoSmithKline plc. (UK)
Hologic, Inc. (USA)
Lab 21 Limited (UK)
Macrogen, Inc. (Korea)
NeoGenomics Laboratories, Inc. (USA)
Novartis AG (Switzerland)
QIAGEN NV (The Netherlands)
Rosetta Genomics Ltd (Israel)
Thermo Fisher Scientific Inc. (USA)

7. GLOBAL MARKET PERSPECTIVE

Table 14. World Recent Past, Current and Future Analysis for Personalized Medicines by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific (excluding Japan) and Rest of World Markets Independently Analyzed with Annual Revenue Figures in US$ Million for Years 2016 through 2024 (includes corresponding Graph/Chart)

Table 15. World Historic Review for Personalized Medicines by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific (excluding Japan) and Rest of World Markets Independently Analyzed with Annual Revenue Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart)

Table 16. World 14-Year Perspective for Personalized Medicines by Geographic Region - Percentage Breakdown of Revenues for US, Canada, Japan, Europe, Asia-Pacific (excluding Japan) and Rest of World Markets for Years 2011, 2017 and 2024 (includes corresponding Graph/Chart)

By Segment

Table 17. World Recent Past, Current and Future Analysis for Targeted Therapeutics by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific (excluding Japan) and Rest of World Markets Independently Analyzed with Annual Revenue Figures in US$ Million for Years 2016 through 2024 (includes corresponding Graph/Chart)

Table 18. World Historic Review for Targeted Therapeutics by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific (excluding Japan) and Rest of World Markets Independently Analyzed with Annual Revenue Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart)

Table 19. World 14-Year Perspective for Targeted Therapeutics by Geographic Region - Percentage Breakdown of Revenues for US, Canada, Japan, Europe, Asia-Pacific (excluding Japan) and Rest of World Markets for Years 2011, 2017 and 2024 (includes corresponding Graph/Chart)

Table 20. World Recent Past, Current and Future Analysis for Tests & Lab Services for Personalized Medicine by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific (excluding Japan) and Rest of World Markets Independently Analyzed with Annual Revenue Figures in US$ Million for Years 2016 through 2024 (includes corresponding Graph/Chart)

Table 21. World Historic Review for Tests & Lab Services for Personalized Medicine by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific (excluding Japan) and Rest of World Markets Independently Analyzed with Annual Revenue Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart)

Table 22. World 14-Year Perspective for Tests & Lab Services for Personalized Medicine by Geographic Region - Percentage Breakdown of Revenues for US, Canada, Japan, Europe, Asia-Pacific (excluding Japan) and Rest of World Markets for Years 2011, 2017 and 2024 (includes corresponding Graph/Chart)

III. MARKET

1. THE UNITED STATES

A. Market Analysis
Outlook
US Individualized Medicine Market to Witness Significant Growth
Companies and Investors Bullish on Personalized Medicine Market in the US
Government Agencies Push for Personalized Medicines
Personalized Medicine Regulations in the FDA – Changing for the Better
FDA Approvals of Personalized Medicines Continue to Rise
FDA Approved Personalized Medicines: 2016 & 2017
FDA Approval of Keytruda to Stimulate Personalized Medicine Development
Challenges for FDA in Approving Personalized Drugs
Increasing Burden of Chronic Diseases Drives Focus onto Personalized Treatment
Cancer Statistics in the US

Table 23. New Cancer Cases by Gender and Affected Site in the US (2017E) (includes corresponding Graph/Chart)

Table 24. Cancer Related Deaths by Gender and Affected Site in the US (2017E) (includes corresponding Graph/Chart)

Table 25. New Cancer Cases in the US by State (2017E) (includes corresponding Graph/Chart)

Table 26. Number of Deaths Related to Major Types of Cancer in US by State: 2017E (includes corresponding Graph/Chart)

Impending Patient Cliff to Drive Opportunities for Personalized Medicine
Personalized Medicine Creating Opportunities for Diagnostics Testing Services
Molecular Diagnostics: Promising Growth Opportunities
Genetic and Genomic Clinical Lab Testing Market: Promising Prospects
Personalized Marketing Key to Growth in Personalized Medicines Market
Growing Efforts behind Brining AI into Medicine
Challenges Persist for the Personalized Medicine Market
Strategic Corporate Developments
Select Players
B. Market Analytics

Table 27. The US Recent Past, Current and Future Analysis for Personalized Medicines by Segment - Targeted Therapeutics and Tests & Lab Services Markets Independently Analyzed with Annual Revenue Figures in US$ Million for Years 2016 through 2024 (includes corresponding Graph/Chart)

Table 28. The US Historic Review for Personalized Medicines by Segment - Targeted Therapeutics and Tests & Lab Services Markets Independently Analyzed with Annual Revenue Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart)

Table 29. The US 14-Year Perspective for Personalized Medicines by Segment - Percentage Breakdown of Revenues for Targeted Therapeutics and Tests & Lab Services Markets for Years 2011, 2017 and 2024 (includes corresponding Graph/Chart)

2. CANADA

A. Market Analysis
Outlook
Rising Incidence of Chronic Diseases Spurs Need for Personalized Medicines

Table 30. New Cancer Cases in Canada (2017E): Breakdown of Cancer Incidence by Gender and Affected Site (includes corresponding Graph/Chart)

Table 31. New Cancer Cases in Canada by Province: 2017E (includes corresponding Graph/Chart)

Table 32. New Cancer Cases in Canada by Age Group: 2017E (includes corresponding Graph/Chart)

Table 33. Cancer Related Deaths in Canada (2017E): Percentage Breakdown of Number of Deaths by Gender and Affected Site (includes corresponding Graph/Chart)

Strategic Corporate Developments
B. Market Analytics

Table 34. Canadian Recent Past, Current and Future Analysis for Personalized Medicines by Segment - Targeted Therapeutics and Tests & Lab Services Markets Independently Analyzed with Annual Revenue Figures in US$ Million for Years 2016 through 2024 (includes corresponding Graph/Chart)

Table 35. Canadian Historic Review for Personalized Medicines by Segment - Targeted Therapeutics and Tests & Lab Services Markets Independently Analyzed with Annual Revenue Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart)

Table 36. Canadian 14-Year Perspective for Personalized Medicines by Segment - Percentage Breakdown of Revenues for Targeted Therapeutics and Tests & Lab Services Markets for Years 2011, 2017 and 2024 (includes corresponding Graph/Chart)

3. JAPAN

A. Market Analysis
Outlook
Demographics Drive Market Growth

Table 37. Japanese Population by Age Group (2017E): Percentage Breakdown for 0-14 Years, 15-24 Years, 25-54 Years, 55-64 Years, 64 Years and Above (includes corresponding Graph/Chart)

Strategic Corporate Development
B. Market Analytics

Table 38. Japanese Recent Past, Current and Future Analysis for Personalized Medicines by Segment - Targeted Therapeutics and Tests & Lab Services Markets Independently Analyzed with Annual Revenue Figures in US$ Million for Years 2016 through 2024 (includes corresponding Graph/Chart)

Table 39. Japanese Historic Review for Personalized Medicines by Segment - Targeted Therapeutics and Tests & Lab Services Markets Independently Analyzed with Annual Revenue Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart)

Table 40. Japanese 14-Year Perspective for Personalized Medicines by Segment - Percentage Breakdown of Revenues for Targeted Therapeutics and Tests & Lab Services Markets for Years 2011, 2017 and 2024 (includes corresponding Graph/Chart)

4. EUROPE

A. Market Analysis
Outlook
European Personalized Medicine Market to Exhibit Robust Growth
Aging Population to Drive Demand for Personalized Medicines

Table 41. EU-28 Country-wise Statistics of 65+ Population as % of Total Population: 2016 (includes corresponding Graph/Chart)

Insight into Molecular Diagnostics Markets in Europe
Regulatory Scenario in Europe for Companion Diagnostics
Companion Diagnostics: Select European Players with Strong Biomarker Pipeline
The Need for Improving Reimbursement Policies
Europe Heading towards Massive Improvements in Personalized Medicine
Personalized Medicine Big on EU Agenda – A Peek into EC Investments in This Space
B. Market Analytics

Table 42. European Recent Past, Current and Future Analysis for Personalized Medicines by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets Independently Analyzed with Annual Revenue Figures in US$ Million for Years 2016 through 2024 (includes corresponding Graph/Chart)

Table 43. European Historic Review for Personalized Medicines by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets Independently Analyzed with Annual Revenue Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart)

Table 44. European 14-Year Perspective for Personalized Medicines by Geographic Region - Percentage Breakdown of Revenues for France, Germany, Italy, UK and Rest of Europe Markets for Years 2011, 2017 and 2024 (includes corresponding Graph/Chart)

Table 45. European Recent Past, Current and Future Analysis for Personalized Medicines by Segment - Targeted Therapeutics and Tests & Lab Services Markets Independently Analyzed with Annual Revenue Figures in US$ Million for Years 2016 through 2024 (includes corresponding Graph/Chart)

Table 46. European Historic Review for Personalized Medicines by Segment - Targeted Therapeutics and Tests & Lab Services Markets Independently Analyzed with Annual Revenue Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart)

Table 47. European 14-Year Perspective for Personalized Medicines by Segment - Percentage Breakdown of Revenues for Targeted Therapeutics and Tests & Lab Services Markets for Years 2011, 2017 and 2024 (includes corresponding Graph/Chart)

4A. FRANCE

A. Market Analysis
Outlook
Strategic Corporate Development
biomérieux SA – A Key Player
B. Market Analytics

Table 48. French Recent Past, Current and Future Analysis for Personalized Medicines by Segment - Targeted Therapeutics and Tests & Lab Services Markets Independently Analyzed with Annual Revenue Figures in US$ Million for Years 2016 through 2024 (includes corresponding Graph/Chart)

Table 49. French Historic Review for Personalized Medicines by Segment - Targeted Therapeutics and Tests & Lab Services Markets Independently Analyzed with Annual Revenue Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart)

Table 50. French 14-Year Perspective for Personalized Medicines by Segment - Percentage Breakdown of Revenues for Targeted Therapeutics and Tests & Lab Services Markets for Years 2011, 2017 and 2024 (includes corresponding Graph/Chart)

4B. GERMANY

A. Market Analysis
Outlook
Strategic Corporate Development
B. Market Analytics

Table 51. German Recent Past, Current and Future Analysis for Personalized Medicines by Segment - Targeted Therapeutics and Tests & Lab Services Markets Independently Analyzed with Annual Revenue Figures in US$ Million for Years 2016 through 2024 (includes corresponding Graph/Chart)

Table 52. German Historic Review for Personalized Medicines by Segment - Targeted Therapeutics and Tests & Lab Services Markets Independently Analyzed with Annual Revenue Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart)

Table 53. German 14-Year Perspective for Personalized Medicines by Segment - Percentage Breakdown of Revenues for Targeted Therapeutics and Tests & Lab Services Markets for Years 2011, 2017 and 2024 (includes corresponding Graph/Chart)

4C. ITALY

Market Analysis

Table 54. Italian Recent Past, Current and Future Analysis for Personalized Medicines by Segment - Targeted Therapeutics and Tests & Lab Services Markets Independently Analyzed with Annual Revenue Figures in US$ Million for Years 2016 through 2024 (includes corresponding Graph/Chart)

Table 55. Italian Historic Review for Personalized Medicines by Segment - Targeted Therapeutics and Tests & Lab Services Markets Independently Analyzed with Annual Revenue Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart)

Table 56. Italian 14-Year Perspective for Personalized Medicines by Segment - Percentage Breakdown of Revenues for Targeted Therapeutics and Tests & Lab Services Markets for Years 2011, 2017 and 2024 (includes corresponding Graph/Chart)

4D. THE UNITED KINGDOM

A. Market Analysis
Outlook
Initiatives Supporting the Personalized Medicine Market
Strategic Corporate Development
Select Players
B. Market Analytics

Table 57. UK Recent Past, Current and Future Analysis for Personalized Medicines by Segment - Targeted Therapeutics and Tests & Lab Services Markets Independently Analyzed with Annual Revenue Figures in US$ Million for Years 2016 through 2024 (includes corresponding Graph/Chart)

Table 58. UK Historic Review for Personalized Medicines by Segment - Targeted Therapeutics and Tests & Lab Services Markets Independently Analyzed with Annual Revenue Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart)

Table 59. UK 14-Year Perspective for Personalized Medicines by Segment - Percentage Breakdown of Revenues for Targeted Therapeutics and Tests & Lab Services Markets for Years 2011, 2017 and 2024 (includes corresponding Graph/Chart)

4E. REST OF EUROPE

A. Market Analysis
Outlook
Spain – Poised to become a Reckoning Force in Personalized Medicines
Slovenia – Moving Ahead with Use of Supercomputing in Managing Genetic Data
Select Players
B. Market Analytics

Table 60. Rest of Europe Recent Past, Current and Future Analysis for Personalized Medicines by Segment - Targeted Therapeutics and Tests & Lab Services Markets Independently Analyzed with Annual Revenue Figures in US$ Million for Years 2016 through 2024 (includes corresponding Graph/Chart)

Table 61. Rest of Europe Historic Review for Personalized Medicines by Segment - Targeted Therapeutics and Tests & Lab Services Markets Independently Analyzed with Annual Revenue Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart)

Table 62. Rest of Europe 14-Year Perspective for Personalized Medicines by Segment - Percentage Breakdown of Revenues for Targeted Therapeutics and Tests & Lab Services Markets for Years 2011, 2017 and 2024 (includes corresponding Graph/Chart)

5. ASIA-PACIFIC

A. Market Analysis
Outlook
Healthcare Spending in Asia-Pacific: On the Rise
China and India: Two Fast-Growing Markets
Focus on Select Region
India
Growing Investments in Pharmacogenomics Research Drives Personalized Medicine
Challenges Ahead…
Strategic Corporate Developments
Macrogen, Inc. (Korea) – A Key Player
B. Market Analytics

Table 63. Asia-Pacific Recent Past, Current and Future Analysis for Personalized Medicines by Segment - Targeted Therapeutics and Tests & Lab Services Markets Independently Analyzed with Annual Revenue Figures in US$ Million for Years 2016 through 2024 (includes corresponding Graph/Chart)

Table 64. Asia-Pacific Historic Review for Personalized Medicines by Segment - Targeted Therapeutics and Tests & Lab Services Markets Independently Analyzed with Annual Revenue Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart)

Table 65. Asia-Pacific 14-Year Perspective for Personalized Medicines by Segment - Percentage Breakdown of Revenues for Targeted Therapeutics and Tests & Lab Services Markets for Years 2011, 2017 and 2024 (includes corresponding Graph/Chart)

6. REST OF WORLD

A. Market Analysis
Outlook
Strategic Corporate Development
Rosetta Genomics Ltd (Israel) – A Key Player
B. Market Analytics

Table 66. Rest of World Recent Past, Current and Future Analysis for Personalized Medicines by Segment - Targeted Therapeutics and Tests & Lab Services Markets Independently Analyzed with Annual Revenue Figures in US$ Million for Years 2016 through 2024 (includes corresponding Graph/Chart)

Table 67. Rest of World Historic Review for Personalized Medicines by Segment - Targeted Therapeutics and Tests & Lab Services Markets Independently Analyzed with Annual Revenue Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart)

Table 68. Rest of World 14-Year Perspective for Personalized Medicines by Segment - Percentage Breakdown of Revenues for Targeted Therapeutics and Tests & Lab Services Markets for Years 2011, 2017 and 2024 (includes corresponding Graph/Chart)

IV. COMPETITIVE LANDSCAPE

Total Companies Profiled: 87 (including Divisions/Subsidiaries - 95)
The United States (64)
Canada (4)
Japan (3)
Europe (17)
  France (5)
  Germany (3)
  The United Kingdom (3)
  Rest of Europe (6)
Asia-Pacific (Excluding Japan) (6)
Latin America (1)